Science

Having long been recognised as crucial mediators of innate immunity, neutrophils provide the first line of defence against invading microorganisms and inflammatory insults, capable of mobilizing innate and adaptive responses to return to homeostasis.

 

At LIfT Biosciences, we are harnessing the innate properties of Immunomodulatory Alpha Neutrophils (IMANs) that exhibit exceptional cytotoxic and immunomodulatory capacity for the treatment of solid tumour indications. LIfT is the only Biotech company in the world with a Neutrophil Based Cell Therapy Platform.

​

N-LIfT cells differentiate in vivo into Immunomodulatory Alpha Neutrophils (IMANs) that have the potential to overcome hurdles encountered by other cell therapies in the treatment of solid tumours. N-LIfT cells are:

• Allogeneic, straightforward to scale, cost effective and off-the-shelf 

• Innate antigen-independent mechanism-of-action

• Actively recruited into the tumour microenvironment

• Stable and capable of overcoming immunosuppressive tumour microenvironments

• Capable of orchestrating patients own anti-tumour immune responses